US and UK Finalize Duty-Free Accord on Prescription Drugs.
The UK and US have signed a significant trade agreement that will ensure zero duties on British medicine exports going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the National Health Service (NHS). This move secures that tariffs on these vital goods will be held at nothing for a period of 36 months.
This development comes after earlier statements to significantly raise import taxes on branded pharmaceutical products, with increases discussed up to one hundred percent.
"This agreement between the United Kingdom bolsters the global environment for innovative medicines and establishes long-overdue fairness to transatlantic medicine commerce," a statement said.
Economic Impact
Pharmaceuticals represent one of the UK's most significant exports to the US, which is easily the biggest market for major UK drugmakers.
Export figures indicate that in the 12 months leading up to September, the UK sold medicines worth billions to the US. This value represented a significant portion of total UK exports in that span.
"This agreement secures work, boosts funding and sets the stage for the UK to become a global hub for medical research," a government official commented.
Key NHS Changes
The agreement includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
The pact comes amid a ongoing row between the drug companies and the UK government over spending levels and approval rates.
This friction were intensified by assertions that US patients were paying several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been paused or scrapped, while major investments have been announced toward US facilities.
The Science Minister acknowledged that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
